Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Aug 22, 2023 3:56pm
92 Views
Post# 35600531

RE:RE:RE:RE:Something is cooking!!!

RE:RE:RE:RE:Something is cooking!!!Quadruple PPS would be CAD $5.32/share or $1.33/share pre-split.  So, about where we were a couple of months ago.

Call me crazy but I would like at least CAD $7/share pre-split (basically $28/share)

palinc2000 wrote:

Worst case we get completely wiped out...if sales dont contribute  enough to reach  positive Ebitda ....They have forecasted that sales would reach a high enough  level to generate enough cash,,,I am cautiously optimistic that the guidance will be met,..
If the positive EBITDA is met then we should at least triple or quadruple the SP and more
Signing deals with partners would have a positive  impact   of course but hard to quantify without more details

Lee430 wrote: Palinc, How do you see us shareholder fairing in your possible scenarios? What do you think the worst case or best case might be?
palinc2000 wrote: I may be interpreting this wrong but the newly released Coporate Presentation is like a Term Sheet to be presented to eventual acquirer(s/partners ) in whole or in part .....
They will reduce expenses to the minimum until resolution 


palinc2000 wrote: Restructuring? Take over? Merger? Partnering?
I may be wrong but the only other explanation would be that there has been a gas leak in the Head Office and they are all sleeping LOL!!!








<< Previous
Bullboard Posts
Next >>